Letrozolo Tecnigen (Letrozole)

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. By inhibiting this conversion, systemic estrogen levels fall, depriving estrogen‑dependent cancer cells of a key growth signal and thereby slowing tumor progression.

The specific dose of letrozole is determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. In many treatment protocols, a common starting point is 2.5 mg taken once daily, but the exact regimen must be set by a qualified prescriber.

Letrozolo is not recommended for use during pregnancy or while breastfeeding. There is limited safety data, and the drug may cause fetal harm by disrupting estrogen pathways. Women of child‑bearing potential should use effective contraception during treatment and discuss any concerns with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Letrozolo Tecnigen. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and the necessary import documentation.

Letrozolo, like other third‑generation aromatase inhibitors (e.g., anastrozole, exemestane), offers potent estrogen suppression with a once‑daily oral regimen. Comparative studies suggest similar efficacy, while individual tolerability may differ; letrozolo is often chosen for its favorable pharmacokinetic profile and extensive clinical experience in postmenopausal breast cancer.

Letrozolo Tecnogen tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Letrozolo is administered orally as a tablet, typically swallowed whole with water. It is usually taken once daily, with or without food, as directed by the prescribing clinician. Patients should follow the exact dosing schedule provided by their healthcare professional.

Serious risks include severe bone loss leading to fractures, liver toxicity, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should report any new bone pain, signs of liver dysfunction (e.g., jaundice), or unexplained swelling or shortness of breath to their physician promptly.

Letrozolo is contraindicated in premenopausal women, patients with known hypersensitivity to letrozole or other aromatase inhibitors, and individuals with severe liver impairment. It should also be avoided in patients receiving estrogen‑containing hormone therapy, as the combination negates its therapeutic effect.